18,693 Shares in Bausch Health Companies Inc. (NYSE:BHC) Purchased by Magnetar Financial LLC

Magnetar Financial LLC purchased a new stake in Bausch Health Companies Inc. (NYSE:BHC) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 18,693 shares of the company’s stock, valued at approximately $151,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new position in shares of Bausch Health Companies in the third quarter valued at approximately $938,000. SG Americas Securities LLC increased its stake in Bausch Health Companies by 62.0% in the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company’s stock valued at $26,614,000 after buying an additional 1,263,706 shares during the period. Range Financial Group LLC purchased a new position in Bausch Health Companies during the 4th quarter worth $1,004,000. Geode Capital Management LLC lifted its stake in shares of Bausch Health Companies by 20.5% in the 3rd quarter. Geode Capital Management LLC now owns 636,082 shares of the company’s stock worth $6,448,000 after acquiring an additional 108,269 shares during the period. Finally, Goldentree Asset Management LP boosted its holdings in shares of Bausch Health Companies by 31.0% in the third quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock valued at $239,552,000 after acquiring an additional 6,958,717 shares in the last quarter. 78.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on BHC. Jefferies Financial Group reissued a “hold” rating and set a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada cut their target price on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a research note on Thursday, January 30th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $7.42.

Bausch Health Companies Trading Up 0.5 %

Shares of BHC opened at $7.17 on Monday. Bausch Health Companies Inc. has a twelve month low of $3.96 and a twelve month high of $11.46. The firm has a market capitalization of $2.64 billion, a P/E ratio of -59.70, a PEG ratio of 0.37 and a beta of 0.59. The firm’s 50-day moving average is $7.14 and its two-hundred day moving average is $7.70.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The firm had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. Analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.